NEI Podcast

Join Dr. Andy Cutler as he talks with the co-author of the winning poster from the 2023 NEI Congress Young Investigator Poster Competition, Dr. Richard Price. They discuss the objectives, design, and key findings of the poster titled, "Improved Mood and Weight Gain Mitigation Following Switch from Aripiprazole to Cariprazine." They also discuss the potential implications of these findings and applications of cariprazine in psychiatry. Dr. Richard Price is an Assistant Professor of Clinical Psychiatry at Weill Cornell Medical College. Maxwell Zachary Price, the lead author of the winning poster, is a medical student at Hackensack Meridian School of Medicine. Learn about upcoming NEI Meetings at https://nei.global/meetings

What are the main reasons MAOIs are underutilized in psychiatric practice despite their proven efficacy for certain conditions? What are the key dietary restrictions patients must follow when taking MAOIs? What are the critical drug-drug interactions clinicians must be aware of when prescribing MAOIs? What clinical pearls or tips would you give to clinicians looking to become more comfortable using these agents? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on underutilized psychotropic drugs. Today, Dr. Andy Cutler interviews Dr. Thomas Schwartz and Dr. Stephen Stahl about factors that have led to the underutilization of MAOIs in psychiatry. Let's listen to Part 2 of our theme: Underutilized Psychiatric Drugs. Subscribe to the NEI Podcast, so that you don't miss another episode! Resources Email [email protected] for guidance on prescribing MAO inhibitors The Prescriber's Guide to Classic MAO Inhibitors (Phenelzine, Tranylcypromine, Isocarboxazid) for Treatment-Resistant Depression Practical Guide for Prescribing MAOIs: Debunking Myths and Removing Barriers

What are the current smoking rates among LGBTQIA+ individuals compared to the general population? What unique barriers do LGBTQIA+ individuals face when trying to quit smoking? What are the recommended pharmacotherapies and behavioral interventions for smoking cessation? What training is needed for providers to deliver culturally affirmative smoking cessation treatment for LGBTQIA+ patients? Dr. Rhonda Schwindt is an Associate Professor at The George Washington University School of Nursing. She is a nationally certified Psychiatric-Mental Health Nurse Practitioner with an active clinical practice specializing in LGBTQIA+ health, trauma, and treatment-resistant mood disorders. Dr. Schwindt earned a Doctor of Nursing Practice degree from Case Western Reserve University, a Master of Science in Nursing from Indiana University School of Nursing, a Bachelor of Arts from Purdue University, and a diploma in nursing from St. Elizabeth School of Nursing. Dr. Schwindt has a funded program of research focused on improving health outcomes for the LGBTQIA+ community. She led a team of researchers that examined barriers to, and facilitators of, smoking cessation and treatment utilization in the transgender and gender expansive population as well as studies exploring best practices for teaching graduate students how to provide affirming care. Dr. Schwindt has received international recognition as an outstanding graduate nurse educator and for clinical excellence in the care of persons living with serious mental illness. Resources Pride in Being Tobacco-Free UCSF Smoking Cessation Leadership Center Fenway Health Trevor Project

In this CME episode, Dr. Andrew Cutler interviews Dr. Laxman Bahroo about the current landscape of tardive dyskinesia, including screening, diagnosis, and treatment. Practical strategies based on the latest data are reviewed at length, particularly for long-term management of tardive dyskinesia. Create a free NEI guest account and obtain CME/CE by participating in this activity here: https://nei.global/e228-cme Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp Stay updated with email alerts and join our conversations on social. Follow us on: YouTube: https://nei.global/youtube Instagram: https://nei.global/instagram LinkedIn: https://nei.global/linkedin Facebook: https://nei.global/facebook X: https://nei.global/twitter

What are the properties of lithium that make it a unique treatment option? What are the main reasons why lithium is underutilized in clinical practice, and what are the consequences of underutilization? What are the common myths or misconceptions about lithium's safety and tolerability? How can we better educate patients about the benefits of lithium and address concerns about side effects or monitoring requirements that may impact adherence? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on underutilized psychotropic drugs. Today, Dr. Andy Cutler interviews Dr. Jonathan Meyer and Dr. Stephen Stahl about factors that have led to the underutilization of lithium in psychiatry. Let's listen to Part 1 of our theme: Underutilized Psychiatric Drugs. Subscribe to the NEI Podcast, so that you don't miss another episode! Resource The Lithium Handbook

In this CME episode, Dr. Andrew Cutler interviews Desiree Matthews, PMHNP-BC on the importance of engaging patients across all facets of tardive dyskinesia management beginning with screening to symptoms monitoring to treatment. The role of patient experience and preferences in shared decision-making regarding treatment for tardive dyskinesia is discussed at length. Create a free NEI guest account and obtain CME/CE by participating in this activity here: https://nei.global/e226-cme Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp Stay updated with email alerts and join our conversations on social. Follow us on: YouTube: https://nei.global/youtube Instagram: https://nei.global/instagram LinkedIn: https://nei.global/linkedin Facebook: https://nei.global/facebook X: https://nei.global/twitter

How do symptoms of agitation manifest differently in disorders such as bipolar disorder, schizophrenia, and dementia, and what challenges does this pose for assessment? What are the most effective pharmacological treatments for acute agitation in psychiatric patients, and how do you determine the best course of action? How do cultural factors influence the approach to managing agitation in various mental health conditions? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the "untreatable" dimensions of psychopathology. Today, Dr. Andy Cutler interviews Dr. Leslie Citrome and Dr. Stephen Stahl about the clinical difficulties of treating agitation. Let's listen to Part 3 of our theme: Untreatable Dimensions of Psychopathology. Subscribe to the NEI Podcast, so that you don't miss another episode!

What are the hypothesized neurobiological mechanisms that support the use of cannabidiol (CBD) as a treatment for opioid use disorder (OUD)? How does CBD influence cue-induced craving in OUD? What are the challenges and opportunities in further exploring the use of CBD as a potential treatment for OUD? Dr. Joji Suzuki is the Director of the Division of Addiction Psychiatry and Director of Addictions Education in the Department of Psychiatry, Brigham and Women's Hospital, and an Assistant Professor of Psychiatry at Harvard Medical School. His areas of clinical and research interests are the assessment and management of substance use disorders and related conditions in general medical settings, motivational interviewing, office-based opioid treatment, implementation of collaborative models of care, and medical education. He is the site director for the Partners Addiction Psychiatry Fellowship, and is involved with teaching medical students, residents, and allied health professionals. He has authored over 30 peer-reviewed manuscripts and book chapters related to addiction psychiatry.

In this episode, Dr. David Goodman addresses your unanswered questions from his presentation, Setting the Mood: Strategies for Diagnosing and Treating ADHD in the Context of Bipolar Disorder, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

In this episode, Dr. Manpreet Singh addresses your unanswered questions from her joint presentation, Don't Get Mixed Up! Recognizing and Treating Mixed Features Across the Lifespan, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

In this episode, Dr. Dani Cabral addresses your unanswered questions from her presentation, Memories in the Future: An Update on the Diagnosis and Treatment of Alzheimer's Disease, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

In this episode, Dr. Sarah Vinson addresses your unanswered questions from her panel presentation, Serious Mental Illness: A Collaborative Approach, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

How does dysfunction in cognition affect overall treatment outcomes for psychiatric disorders? What are the challenges in treating cognitive deficits in psychiatric conditions? What treatments are in development for cognitive dysfunction? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the "untreatable" dimensions of psychopathology. Today, Dr. Andy Cutler interviews Dr. Richard Keefe and Dr. Stephen Stahl about the clinical difficulties of treating cognitive dysfunction. Let's listen to Part 2 of our theme: Untreatable Dimensions of Psychopathology. Subscribe to the NEI Podcast, so that you don't miss another episode! ***Register today for the 7th annual NEI Synapse, being held April 19th through the 21st in-person in Las Vegas and online via simulcast. Use discount code PODCAST to save $100 on your registration at nei.global/Synapse.

What are some common challenges faced by caregivers of individuals with dementia? What is comprehensive dementia care and how does it improve quality of life of individuals with dementia and their caregivers? What is the GUIDE Model and why is it needed? Carolyn Clevenger, DNP, RN, GNP-BC, AGPCNP-BC, FAANP, FGSA is a Professor at the Nell Hodgson Woodruff School of Nursing at Emory University. Dr. Clevenger is a nationally recognized educational leader in advanced practice nursing and in geriatrics and gerontology. She is a Past President of the Gerontological Advanced Practice Nurses Association, Fellow of the American Association of Nurse Practitioners (AANP) and the Gerontological Society of America, and contributor to the AANP Certification Program. She is the director of the nurse-led patient centered medical home for people living with dementia, the Integrated Memory Care Clinic (IMCC). IMCC represents an innovative clinical model that provides memory and primary care in a single integrated model for people living with dementia and their care partners. Resources Alzheimer's Association KAER toolkit ROON ***Register today for the 7th annual NEI Synapse, being held April 19th through the 21st in-person in Las Vegas and online via simulcast. Use discount code PODCAST to save $100 on your registration at nei.global/Synapse.

What is the role of mindfulness techniques in the treatment of anxiety disorders and how is it evolving? How does mindfulness-based stress reduction compare to pharmacological treatment for anxiety disorders? What are the hypotheses that have been made about why mindfulness-based treatments work for anxiety? Elizabeth Hoge, MD is a Professor and Director of the Anxiety Disorders Research Program in the Department of Psychiatry at Georgetown University School of Medicine. Dr. Hoge completed her psychiatry residency training and research fellowship at the Massachusetts General Hospital in Boston. During her research fellowship, she earned a Masters in Medical Science from the Harvard Medical School-Massachusetts Institute of Technology program in Health Sciences and Technology with a focus on clinical trials. Her research focuses on treatments for anxiety disorders, including medication, psychotherapy and mindfulness, and the examination of biomarkers of anxiety, stress, and trauma. She has over 50 publications in the medical research literature and is on the Scientific Council of the Anxiety and Depression Association of America. ***Register today for the 7th annual NEI Synapse, being held April 19th through the 21st in-person in Las Vegas and online via simulcast. Use discount code PODCAST to save $100 on your registration at nei.global/Synapse.

What are the cultural factors that should be considered when providing mental health care to migrant and refugee populations? What challenges and opportunities exist in providing mental health care to these communities? How can mental health professionals collaborate with other disciplines to create a holistic approach to address the mental health needs of migrant and refugee populations? Lisa Fortuna, MD, MPH is the Chief of Psychiatry and Neurosciences at the Riverside School of Medicine. She was the Chief of Psychiatry and Vice-Chair at Zuckerberg San Francisco General Hospital/UCSF and Associate Professor of Clinical Psychiatry. She has been an investigator on several National Institutes of Health and foundation-funded studies of Latino and immigrant mental health, integrated care, access to care including a principle investigator of a NIMH funded R01 aimed at optimizing family navigation for addressing child behavioral health in primary care and a Patient Centered Outcome Research Institute (PCORI) funded multi-site large pragmatic trial on the treatment of childhood anxiety comparing face to face vs. digitally delivered CBT in English and Spanish called Kids FACE FEARS. Her areas of expertise are child and adolescent psychiatry, treatment and research on PTSD across the lifespan, immigrant mental health and disparities/ access to care including digital interventions research.

How does anhedonia impact the overall treatment plan for patients with major depressive disorder and other psychiatric conditions? What are some of the most challenging aspects of treating anhedonia in patients? Are there any new treatments in development that may be helpful for treating anhedonia? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the "untreatable" dimensions of psychopathology. Today, Dr. Andy Cutler interviews Dr. Vladmir Maletic and Dr. Stephen Stahl about the clinical difficulties of treating anhedonia Let's listen to Part 1 of our theme: Untreatable Dimensions of Psychopathology. Subscribe to the NEI Podcast, so that you don't miss another episode!

During Black History Month, we revisit an enlightening conversation with Dr. Sarah Vinson about the impact of structural racism on Black mental health and how mental healthcare providers can make a difference in the lives of patients by leveraging their privilege and skillsets. Dr. Sarah Y. Vinson is a physician who is triple-board certified in adult, child & adolescent, and forensic psychiatry. She is the founder of the Lorio Psych Group, an Atlanta, GA based mental health practice providing expert care and consultation. Dr. Vinson is also the founder of Lorio Forensics, which provide consultation on a wide variety of cases in criminal, civil, and family court cases. After graduating from medical school at the University of Florida with Research Honors and as an Inductee in the Chapman Humanism Honors Society, she completed her general psychiatry training at Cambridge Health Alliance/Harvard Medical School. While there, she also received specialized training in trauma through the Victims of Violence Program. She then returned to the South to complete fellowships in both child & adolescent and forensic psychiatry at Emory University School of Medicine. In addition to providing mental health care services such as psychotherapy, consultation, and psychopharmacology through her private practice, Dr. Vinson is a Professor and Chair of the Department of Psychiatry & Behavioral Sciences at Morehouse School of Medicine. She is also Adjunct Faculty at Emory University School of Medicine. She is the Past President of the Georgia Council on Child and Adolescent Psychiatry, and the Treasurer of the Georgia Psychiatric Physicians Association. Additionally, she is an Advisor for the Judges Psychiatry Leadership Initiative. Dr. Vinson has been a speaker at national conferences including the American Psychiatric Association Annual Meeting, the American Academy of Child and Adolescent Psychiatry Annual Meeting and The National Urban League Annual Meeting. Dr. Vinson has received numerous awards in recognition of her service and leadership including the University of Florida College of Medicine Outstanding Young Alumna Award and the APA Jeanne Spurlock Minority Fellowship Alumna Achievement Award. Resources Social (In)justice in Mental Health Judges and Psychiatrists Leadership Initiative Ourselves Black

Can the therapeutic benefits of psilocybin be achieved without a psychedelic trip? What is the role of psychological support in the therapeutic effect of psilocybin? What is microdosing and what are its potential benefits and risks? What is the path to FDA approval and commercialization of psilocybin and other psychedelics? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the role of psychedelics in modern psychiatry. Today, Dr. Andy Cutler interviews Dr. Charles Raison and Dr. Stephen Stahl about the importance of the psychedelic trip for the therapeutic benefits of psilocybin. Let's listen to Part 4 of our theme: Classic Psychedelics for the Modern Psychopharmacologist. Subscribe to the NEI Podcast, so that you don't miss another episode!

The climate crisis has a wide-reaching impact that negatively affects both acute and long-lasting mental health outcomes. Are there specific populations that are more vulnerable to mental health issues related to the climate crisis? What is the role of mental health professional to combat the negative influence of climate change on mental health? Robin Cooper, MD, is a psychiatrist who has had a private practice in San Francisco for 40 years, is Associate Clinical Professor in the Department of Psychiatry and Behavioral Sciences at the UCSF Medical School, where she is actively involved in efforts to address climate change impacts on mental health and health. She is co-founder of Climate Psychiatry Alliance, a national group of psychiatrists and mental health professionals dedicated to understanding, educating, and advocating about the specific impact of climate change on mental health. As she moves into semi-retirement in her clinical work, her work around climate change impacts on health and mental health have become a second career. Resources Climate Psychiatry Alliance https://www.climatepsychiatry.org Coping with Extreme Health https://www.climatepsychiatry.org/heat-wave-resources

In this CME episode, Dr. Andrew Cutler interviews Dr. Dani Cabral about current and novel diagnostic tools and treatments for Alzheimer's disease. Create a free NEI guest account and obtain CME/CE by participating in this activity here: https://nei.global/e211-cme Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp Stay updated with email alerts and join our conversations on social. Follow us on: YouTube: https://nei.global/youtube Instagram: https://nei.global/instagram LinkedIn: https://nei.global/linkedin Facebook: https://nei.global/facebook X: https://nei.global/twitter

What do the clinical trials of psilocybin and other psychedelics show in terms of efficacy and safety? How much of the benefit with psychedelic treatment is attributable to psychological support? Is the psychedelic trip important for the therapeutic benefits of psychedelic treatments? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the role of psychedelics in modern psychiatry. Today, Dr. Andy Cutler interviews Dr. Scott Aaronson and Dr. Stephen Stahl about the potential indications and therapeutic benefits of psilocybin and other psychedelics. Let's listen to Part 3 of our theme: Classic Psychedelics for the Modern Psychopharmacologist. Subscribe to the NEI Podcast, so that you don't miss another episode!

In this CME episode, Dr. Andrew Cutler interviews Dr. Jeffrey Strawn about the role of pharmacogenomic testing in guiding treatment of major depressive disorder (MDD). They discuss how pharmacogenomic testing works, the impact of failed treatments and side effects on patients with MDD, and the clinical applications and future directions of pharmacogenomic testing. Create a free NEI guest account and obtain CME/CE by participating in this activity here: https://nei.global/e209-cme Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp Stay updated with email alerts and join our conversations on social. Follow us on: YouTube: https://nei.global/youtube Instagram: https://nei.global/instagram LinkedIn: https://nei.global/linkedin Facebook: https://nei.global/facebook X: https://nei.global/twitter

What were some new treatments approved by the FDA? What did we learn about the long-term safety of methylphenidate in childhood ADHD? Are there benefits to long-term maintenance treatment with antidepressants in bipolar disorder? What did we learn about the safety and efficacy of subcutaneous racemic ketamine for treatment-resistant depression and MDMA for PTSD? In this episode, Dr. Andrew Cutler and Dr. Roger McIntyre address these questions and so much more about this past year in psychopharmacology. Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function, and medical comorbidity. His work broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. Resources: This Month in Psychopharmacology

In this CME episode, Dr. Andrew Cutler interviews Dr. Vladimir Maletic about the impact of residual symptoms on patients with major depressive disorder, as well as treatment modifications to address residual symptoms in these individuals. Create a free NEI guest account and obtain CME/CE by participating in this activity here: https://nei.global/e207-cme Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp Stay updated with email alerts and join our conversations on social. Follow us on: YouTube: https://nei.global/youtube Instagram: https://nei.global/instagram LinkedIn: https://nei.global/linkedin Facebook: https://nei.global/facebook X: https://nei.global/twitter

In this episode, Dr. Vladimir Maletic addresses your unanswered questions from his presentations, "From Despair to Delight: Advances in the Diagnosis and Treatment of Anhedonia" and "Ho Hum to Aha! Treating Anhedonia and Emotional Blunting."

In this episode, Dr. Leslie Citrome addresses your unanswered questions from his presentation, There's No Place Like Home: Addressing Agitation in Dementia.

What is the role of the 5HT2A receptor in the therapeutic actions of psychedelics? What additional mechanisms may be involved in the therapeutic benefits of classic psychedelics? Is the psychedelic trip necessary for the therapeutic benefit of psychedelics? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the role of psychedelics in modern psychiatry. Today, Dr. Andy Cutler interviews Dr. Roger McIntyre and Dr. Stephen Stahl about the current understanding of the neurobiological mechanisms underlying the therapeutic benefits of psychedelics. Let's listen to Part 2 of our theme: Classic Psychedelics for the Modern Psychopharmacologist. Subscribe to the NEI Podcast, so that you don't miss another episode!

In this episode, Dr. Laxman Bahroo addresses your unanswered questions from his presentation, Neurology for Psychiatrists.

In this episode, Dr. Roger McIntyre addresses your unanswered questions from his presentation, Unveiling the Therapeutic Potential: Evidence Supporting the Use of Psychedelics for PTSD, SUD, and Other Indications, at the Pre-Conference Psychedelics Workshop.

In this episode, Dr. Timothy Wilens addresses your unanswered questions from his presentation, Double Trouble: Diagnosis and Pharmacotherapy of ADHD and Juvenile Bipolar Disorder, at the Child & Adolescent Psychiatry Academy.

In this episode, Dr. Robyn Thom addresses your unanswered questions from her presentation, The Full Picture: Managing Autism Spectrum Disorder and Its Frequent Psychiatric Comorbidities, at the Child & Adolescent Psychiatry Academy.

In this episode, Dr. Jeffrey Strawn addresses your unanswered questions from his presentation, Along for the Ride: Treatment Considerations for Childhood Psychiatric Disorders With Co-Occurring Anxiety, at the Child & Adolescent Psychiatry Academy.

Stigma surrounding mental illness and its treatment can be pervasive and negatively impact the quality of life of patients suffering with mental health problems. What role do psychiatric healthcare providers play in addressing and combating mental illness stigma? How do cultural factors influence the perception of mental illness and stigma? What are the best strategies for reducing stigma related to mental illness? Dawn I. Velligan, PhD is a Professor in the Department of Psychiatry, Chief of the Division of Community Recovery, Research and Training, and the Henry B. Dielmann Chair at the University of Texas Health Science Center in San Antonio, Texas. Dr. Velligan's internationally recognized research program focuses on the development and testing of psychosocial treatments to improve medication interest, follow-through, and outcomes for people with schizophrenia. She developed cognitive adaptation training; a treatment designed to improve functional outcomes for people with serious mental illness. Dr. Velligan is an author of numerous publications in high impact journals and has received grant funding from the National Institutes of Health, The National Alliance for Research on Schizophrenia and Depression, industry, and private foundations.

The 19th annual NEI Congress is upon us. Whether you've already secured your spot to join us in person at The Broadmoor in Colorado Springs or plan to attend virtually via simulcast OR are still unsure if this event is for you, you're in luck. This is our Congress preview episode. Congress chairman, Dr. Andrew Cutler interviews a few of the brilliant faculty members who will be speaking at this year's conference for a sneak peek of their presentations and finds out what they are looking forward to at the upcoming event. Register now for 2023 NEI Congress at: https://nei.global/23cng-REG_neipod

What are classic psychedelic drugs and how has their role in psychiatry changed over time? What are the potential benefits of using psychedelic therapy for treating psychiatric disorders? Are there any significant risks and what are the potential side effects associated with psychedelic therapy? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the role of psychedelics in modern psychiatry. Today, Dr. Andy Cutler interviews Dr. Stephen Stahl on the current state of psychedelic research in psychiatry. Let's listen to Part 1 of our theme: Classic Psychedelics for the Modern Psychopharmacologist. Subscribe to the NEI Podcast, so that you don't miss another episode!

How large of an issue is treatment non-adherence in the serious mental illness (SMI) population? How does therapeutic alliance influence treatment adherence? What are some effective strategies for improving medication adherence? Dr. Andrew Cutler interviews Dr. Peter Weiden to find answers to these questions and more! Peter J. Weiden, MD is an internationally recognized expert in the treatment of schizophrenia and related psychotic disorders. Dr. Weiden has a distinguished career spanning academia, clinical trials, and industry. His academic career included positions as Professor of Psychiatry at SUNY Downstate Medical Center from 1999-2007 and at UIC Medical Center from 2007-2014. Dr. Weiden served as Chief Medical Officer for Uptown Research in Chicago and continued as clinical investigator of new and emerging treatments for schizophrenia. His industry experience includes joining Alkermes to focus on development of new treatments for schizophrenia, including the long-acting formulation aripiprazole lauroxil and the combination product olanzapine/samidorphan. He joined Karuna Therapeutics in 2020 to support development of the investigational muscarinic agonist xanomeline-trospium, currently in phase 3 development for the treatment of schizophrenia. This year, Dr. Weiden returned to clinical practice and provides consulting and educational services via PJWeiden, LLC. His areas of expertise include drug development, clinical trials, and clinician education.

In this re-release episode, Dr. Andrew Cutler interviews Dr. Katherine Warburton about the history of criminalization of serious mental illness, the efforts to decriminalize mental illness, and the development and success of diversion programs. Dr. Katherine Warburton is Medical Director/Deputy Director of Clinical Operations for the California Department of State Hospitals. Prior to that, she was the Chief of Forensic Psychiatry at Napa State Hospital. She is on the volunteer clinical faculty of the UC Davis Division of Psychiatry and the Law. Link to "Decriminalizing Mental Illness" by Drs. Warburton and Stahl: https://www.amazon.com/Decriminalizing-Mental-Illness-Katherine-Warburton/dp/1108826954/ref=sr_1_1?crid=18XJ6RE7Y5X5M&keywords=warburton+stahl&qid=1657746214&sprefix=warburton+stahl%2Caps%2C112&sr=8-1

During National Recovery Month, we are re-releasing this classic episode in which Dr. Sabrina Segal interviews addiction expert Dr. Nzinga Harrison about the need to address stigma and misconceptions surrounding the topic of addiction. When it comes to addiction, there are many questions. What does it mean to say that someone is in recovery? What are some behavioral addictions that most people don't think about? Are there such things as healthy addictions? In this episode, Dr. Harrison shares a refreshing and novel perspective on the topics of addiction and recovery. A well-respected physician and educator, Dr. Harrison is the host of the In Recovery weekly podcast by Lemonada Media, in which she engages a large audience on all things addiction with the goal of leading with compassion, evidence and reducing stigma. She is Chief Medical Officer and Co-Founder of Eleanor Health, an innovative company that provides comprehensive, longitudinal outpatient care for individuals experiencing opioid and other substance use disorders. She earned her bachelor's degree in biology with Spanish and Chemistry minors at Howard University, completed medical school at the University of Pennsylvania School of Medicine and General Psychiatry Residency at Emory University. She is Board-Certified in both Adult General Psychiatry and Addiction Medicine and has spent her career treating individuals with Serious Persistent Mental Illness and Addictive Diseases. Currently she holds adjunct faculty appointments at the Morehouse School of Medicine Department of Psychiatry is Co-Founder of Physicians for Criminal Justice Reform, Inc. and Campaign Psychiatrist for Let's Get Mentally Fit, a public education and stigma-reduction campaign. Resources: Dr. Nzinga Harrison's In Recovery Podcast: https://www.lemonadamedia.com/show/in-recovery/ Eleanor Health: https://www.eleanorhealth.com

In this re-release episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl about the dark side of neuroplasticity, or pathologic neuroplasticity, and what we may be able to do to combat it.

What led you to pursue a career in auditory neuroscience and what is the mission behind your laboratory, Brainvolts? What is the effect of bilingualism on Alzheimer's disease? How can sound be used for the assessment of traumatic brain injury and other neurological conditions? In this episode, Dr. Nina Kraus addresses these questions and much more about the clinical applications for auditory neuroscience research. Her laboratory at Northwestern University, Brainvolts, has discovered how to measure the biology of auditory processing with unprecedented precision. The implications of the research conducted there extends beyond the laboratory to schools, community centers, and clinics. Nina Kraus, Ph.D. is a professor at Northwestern University who studies the biology of auditory learning. Through a series of innovative studies involving thousands of research participants from birth to age 90, her research has found that our lives in sound, for better (musicians, bilinguals) or worse (language disorders, concussion, aging, hearing loss), shape auditory processing. She continues to conduct parallel experiments in animal models to elucidate the mechanisms underlying these phenomena. Never having accepted a lack of technology as a roadblock to scientific discovery, Kraus has invented new ways to measure the biology of sound processing in humans that provide precision and granularity in indexing brain function. With her technological innovations she is now pushing science beyond the traditional laboratory by conducting studies in schools, community centers, and clinics. Using the principles of neuroscience to improve human communication, she advocates for best practices in education, health, and social policy. Dr. Kraus is the author of the book "Of Sound Mind: How our Brain Constructs a Meaningful Sonic World." Resources: Brainvolts: https://brainvolts.northwestern.edu/about-us/ Learn more about Of Sound Mind: How our Brain Constructs a Meaningful Sonic World: https://www.amazon.com/Sound-Mind-Brain-Constructs-Meaningful/dp/0262045869# BEAMS hypothesis: https://brainvolts.northwestern.edu/wp-content/uploads/2021/07/Kraus_BEAMS_2021-1.pdf

In this CME episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Sarah Vinson about the ethicality and morality of involuntary treatment for serious mental illness (SMI), the relationship between SMI and the criminal justice system, and community-based changes that are being pursued to improve treatment and reduce the criminalization of SMI. Create a free NEI guest account and obtain CME/CE by participating in this activity here: https://nei.global/e190-cme Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp Stay updated with email alerts and join our conversations on social. Follow us on: YouTube: https://nei.global/youtube Instagram: https://nei.global/instagram LinkedIn: https://nei.global/linkedin Facebook: https://nei.global/facebook X: https://nei.global/twitter

In this re-release episode, Dr. Andrew Cutler interviews Drs. Marko Perko and Stephen Stahl about their book, Tesla: His Tremendous and Troubled Life, which explores the intersection between Tesla's genius, his creativity, and his bipolar disorder. Sadly, Dr. Marko Perko passed away last fall after a battle with cancer. He was a prolific writer and a great mind, and we re-release this episode in his honor. Learn more about Tesla: His Tremendous and Trouble Life

NEI Podcast is taking a temporary hiatus over the summer. From July through September, we will revisit some of our most compelling episodes, on topics that remain as relevant today as when they first aired. New episodes will resume in the fall; make sure you are subscribed so that you don't miss out! ***************************** What is unique about collaborative care when it comes to mental health? Can you share some of the step-by-step guide to implementing the core model in clinical practice for collaborative care? In this episode, Dr. Anna Ratzliff answers these questions and much more! Dr. Anna Ratzliff is a national expert on collaborative care, and specifically on training teams to implement and deliver mental health treatment in primary care settings. Her passion for translating complex research ideas into practical real-world applications began when she received her MD and PhD in Anatomy and Neurobiology as part of the Medical Scientist Training Program at the University of California at Irvine. She currently is a Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington, where she has developed additional expertise in suicide prevention training, mental health workforce development, adult learning best practices, and mentorship. Dr. Ratzliff is the Director of the UW Psychiatry Resident Training Program, Co-Director of the AIMS Center (Advancing Integrated Mental Health Solutions), and Director of the UW Integrated Care Training Program for residents and fellows. Resources: AIMS Center Website: http://aims.uw.edu/ Implementation Guide: https://aims.uw.edu/collaborative-care/implementation-guide APA Training: https://www.psychiatry.org/psychiatrists/practice/professional-interests/integrated-care

What are some of the greatest challenges when treating ADHD in the elderly population? Are stimulants safe in the elderly population? How do hormonal changes influence ADD or ADHD in women throughout life? With this special series, brought to you by the NEI Podcast, we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on novel perspectives and novel treatment approaches for Attention Deficit Hyperactivity Disorder (ADHD). Today, Dr. Andy Cutler interviews Dr. David Goodman on treating ADHD across the lifespan. Let's listen in to Part 3 of our theme: Treating ADHD Across the Lifespan. Subscribe to the NEI Podcast, so that you don't miss another episode!

What is avoidant/restrictive food intake disorder or ARFID? How does it differ from other disorders? How are intestinal microbiota involved when it comes to eating disorders? Dr. Cynthia Bulik is a Distinguished Professor of Eating Disorders and Founding Director of the University of North Carolina (UNC) Center of Excellence for Eating Disorders and Professor of Nutrition, Gillings School of Global Public Health; and Associate Director, UNC Center for Psychiatric Genomics. Dr. Bulik's research teams at UNC (Center of Excellence for Eating Disorders-CEED) and Karolinska Institute (Centre for Eating Disorders Innovation-CEDI) are dedicated to deepening our understanding of the underlying biology and genetics of eating disorders and to advancing the evidence base for the treatment of these illnesses. As founder and co-chair of the Eating Disorders Working Group of the Psychiatric Genomics Consortium (PGC-ED), she leads the global effort to identify actionable genomic variation in eating disorders. She is Principal Investigator of the global Eating Disorders Genetics Initiative funded by the National Institute of Mental Health. She is also the Principal Investigator of the largest study of genetic and environmental contributors to avoidant/restrictive food intake disorder (ARFID-GEN), also funded by the National Institute of Mental Health. Together with Ian Carroll, PhD she conducts population-level and intensive longitudinal clinical investigations of the intestinal microbiota in eating disorders. For the past decade, with Donald Baucom, PhD and Jennifer Kirby, PhD she has developed and disseminated a suite of couple-based interventions for anorexia nervosa, bulimia nervosa, and binge-eating disorder (UNITE: UNiting couples In the Treatment of Eating disorders). She also serves as senior faculty on the SAMHSA-funded National Center of Excellence for Eating Disorders (NCEED)—the national authoritative source for information and training in eating disorders. She is dedicated to mentorship of junior investigators, especially women in STEM fields and is passionate about translating science for the public.

What has research demonstrated about the advantages and consequences of telehealth for the treatment of ADHD and mental health? How can we fill the gaps in underserved communities when it comes to telehealth treatment for ADHD? With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on novel perspectives and novel treatment approaches for Attention Deficit Hyperactivity Disorder (ADHD). Today, Dr. Andy Cutler interviews Dr. Greg Mattingly on best practices and guidelines for using telemedicine for the treatment and management of ADHD. Let's listen in to Part 2 of our theme: The Challenges of Treating ADHD Online Subscribe to the NEI Podcast, so that you don't miss another episode!

What are common comorbidities with ASD and how difficult is it to differentiate these conditions from overlapping symptoms of ASD? What guidelines are there for managing agitation in autism spectrum disorder? Robyn Thom, MD, is a child, adolescent, and adult psychiatrist at the Massachusetts General Hospital (MGH) Lurie Center for Autism and co-Director of the MGH Williams Syndrome Program. She is also an Assistant Professor of Psychiatry at Harvard Medical School. She specializes in diagnosing and treating comorbid psychiatric conditions in individuals with autism spectrum disorder and other developmental disabilities including Williams syndrome. Dr. Thom's research interests include psychopharmacology, anxiety disorders, Williams syndrome, medical comorbidity in adults with autism spectrum disorder, and brain aging.

What is the proposed neurocircuitry that underlies attention deficit hyperactivity disorder, or ADHD? What is known about the role of serotonin in ADHD? Particularly the 5HT2C and 5HT7 receptors? With this special series, brought to you by the NEI Podcast, we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on novel perspectives and novel treatment approaches for Attention Deficit Hyperactivity Disorder (ADHD). Today, Dr. Andy Cutler interviews Dr. Stephen Stahl on the current state of ADHD and where the future lies. Let's listen in to Part 1 of our theme: Shifting Focus: A Novel Perspective on Attention Deficit Hyperactivity Disorder (ADHD) Subscribe to the NEI Podcast, so that you don't miss another episode!

In this episode, Dr. Jonathan Meyer addresses your unanswered questions from his presentation: Dopamine Partial Agonists: How They Work and Why They Don't Always Play Nice with Other Antipsychotics.